Cognition Therapeutics Files 8-K on Financials
Ticker: CGTX · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cognition Therapeutics filed an 8-K on Nov 13, 2024, reporting financial condition and results. Details to follow.
AI Summary
Cognition Therapeutics, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as an official update on Cognition Therapeutics' financial status and operational results, which is crucial information for investors and stakeholders to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that inherently increases risk, but rather provides a regulatory update.
Key Players & Entities
- Cognition Therapeutics, Inc. (company) — Registrant
- November 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2500 Westchester Avenue Purchase, NY 10577 (address) — Address of principal executive offices
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not include the specific financial figures or operational details within this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 13, 2024.
What is the state of incorporation for Cognition Therapeutics, Inc.?
Cognition Therapeutics, Inc. is incorporated in Delaware.
Where are the principal executive offices of Cognition Therapeutics, Inc. located?
The principal executive offices of Cognition Therapeutics, Inc. are located at 2500 Westchester Avenue Purchase, NY 10577.
What is the Commission File Number for Cognition Therapeutics, Inc.?
The Commission File Number for Cognition Therapeutics, Inc. is 001-40886.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-13 07:37:33
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CGTX The Nasdaq Stock Mar
Filing Documents
- tm2428074d1_8k.htm (8-K) — 25KB
- tm2428074d1_ex99-1.htm (EX-99.1) — 60KB
- tm2428074d1_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-24-117243.txt ( ) — 282KB
- cgtx-20241113.xsd (EX-101.SCH) — 3KB
- cgtx-20241113_lab.xml (EX-101.LAB) — 33KB
- cgtx-20241113_pre.xml (EX-101.PRE) — 22KB
- tm2428074d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On November 13, 2024, Cognition Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information disclosed under Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release, dated November 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer Date: November 13, 2024